We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Interleukin 2 Therapy for Disseminated Cancer-Reply

Michael T. Lotze, MD; Steven A. Rosenberg, MD, PhD
JAMA. 1987;257(13):1730-1731. doi:10.1001/jama.1987.03390130047019.
Text Size: A A A
Published online


In Reply.—  Our article demonstrated that IL-2 administered in high doses was capable of mediating the regression of cancer in some patients with metastatic melanoma. Subsequent to this report, we have demonstrated that objective responses can be obtained in patients with renal cell cancer and have confirmed the efficacy of IL-2 therapy in additional patients with melanoma. Complete responses have been observed with both IL-2 therapy alone as well as with LAK cells. These are new treatments, but the first patient to show a complete response to therapy with IL-2 and LAK cells is alive without evidence of cancer two years after her original treatment.Dr Moertel's editorial, which focused on the media response to our earlier report of therapy with LAK cells and IL-2,1 published in December 1985, reflects a misunderstanding of a major point of our report. These reports describe our experience with new approaches to immunotherapy


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.